Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CEO Wenbin Jiang sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $10.75, for a total transaction of $215,000.00. Following the completion of the transaction, the chief executive officer now owns 7,881,541 shares of the company’s stock, valued at $84,726,565.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Wenbin Jiang also recently made the following trade(s):
- On Monday, May 9th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $8.01, for a total transaction of $160,200.00.
- On Thursday, April 7th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $10.54, for a total transaction of $210,800.00.
Shares of Cytek Biosciences stock traded down $0.44 during trading hours on Thursday, reaching $10.43. 432,811 shares of the company’s stock were exchanged, compared to its average volume of 977,402. Cytek Biosciences, Inc. has a 1 year low of $7.38 and a 1 year high of $28.70. The company has a market capitalization of $1.40 billion and a P/E ratio of -521.50. The business has a fifty day moving average of $9.88 and a two-hundred day moving average of $13.19.
Several institutional investors and hedge funds have recently made changes to their positions in CTKB. BlackRock Inc. purchased a new stake in shares of Cytek Biosciences in the third quarter valued at about $39,711,000. Citigroup Inc. purchased a new stake in shares of Cytek Biosciences in the third quarter valued at about $48,000. Goldman Sachs Group Inc. acquired a new position in Cytek Biosciences in the third quarter valued at about $1,484,000. Geode Capital Management LLC acquired a new position in Cytek Biosciences in the third quarter valued at about $6,874,000. Finally, FIL Ltd acquired a new position in Cytek Biosciences in the third quarter valued at about $57,092,000. 35.95% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently commented on CTKB. Zacks Investment Research lowered shares of Cytek Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, April 28th. Morgan Stanley cut their price target on shares of Cytek Biosciences from $27.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, February 15th. Piper Sandler dropped their target price on shares of Cytek Biosciences from $17.00 to $12.00 and set a “na” rating for the company in a report on Sunday, May 15th. Finally, The Goldman Sachs Group dropped their target price on shares of Cytek Biosciences from $28.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.75.
Cytek Biosciences Company Profile (Get Rating)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- The Institutions Are Rotating Into Olli’s Bargain Outlet
- Would Netflix acquiring Roku be a positive for the stock?
- Inflation, An Economic Winter Is Approaching
- Microcap Oil-Dri Corporation Is A Buy For Income Investors
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.